Clinical Trials Logo

Multiple Myeloma, Refractory clinical trials

View clinical trials related to Multiple Myeloma, Refractory.

Filter by:

NCT ID: NCT04657861 Recruiting - Clinical trials for Multiple Myeloma in Relapse

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Start date: May 3, 2022
Phase: Early Phase 1
Study type: Interventional

A study of APRIL CAR-T cells therapy for patients with BCMA/TACI positive relapsed and/or refractory multiple myeloma

NCT ID: NCT04603872 Recruiting - Clinical trials for Multiple Myeloma in Relapse

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Start date: November 1, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

NCT ID: NCT04414475 Recruiting - Clinical trials for Multiple Myeloma, Refractory

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM

Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma or selinexor and pomalidomide plus low-dose dexamethasone in participants with relapsed and/or refractory multiple myeloma.